Log in or Sign up for Free to view tailored content for your specialty!
Steatohepatitis/Metabolic Liver Disease News
Predictors of adverse outcomes among patients with NAFLD, COVID-19
Researchers found certain diagnostics linked to adverse outcomes among patients with non-alcoholic fatty liver disease during COVID-19, according to a presentation at Digestive Disease Week.
Genfit announces the release of NASHnext
Genfit, in association with Labcorp, announced the launch of a noninvasive nonalcoholic steatohepatitis test for at-risk patients, according to a press release.
Log in or Sign up for Free to view tailored content for your specialty!
Volume on consults for alcohol-related GI, liver diseases remain elevated throughout COVID-19
Despite ongoing COVID-19 infection control restrictions, volumes of inpatient consults for alcohol-related gastrointestinal and liver diseases had significantly decreased at the onset of the COVID-19 pandemic, but quickly returned to normal levels, according to an expert presentation during a press conference in advance of Digestive Diseases Week.
Spinach consumption, risk for NAFLD among Iranian adults
Researchers found an inverse association between spinach consumption and the risk for nonalcoholic fatty liver disease, according to BMC Gastroenterology.
NAFLD increases risk for hepatocellular carcinoma
Nonalcoholic fatty liver disease correlated with a significantly increased risk for developing cancer overall, due to the significant increased incidence in hepatocellular carcinoma, according to study results.
Exercise beneficial for liver function among men with NAFLD
Exercise provided considerable weight loss-independent benefits in patients with nonalcoholic fatty liver disease, according to research published in JHEP Reports.
VIDEO: Website provides up-to-date data from NASH cirrhosis study
In this video exclusive, Pol Boudes, MD, chief medical officer of Galectin Therapeutics, spoke about NAVIGATEnash.com, a website for physicians and patients to get information on cirrhosis stemming from nonalcoholic steatohepatitis.
BIO89-100 reduces liver fat, lowers triglycerides in adults with NASH
BIO89-100 reduced liver fat in adults with nonalcoholic steatohepatitis, or NASH, while also lowering triglycerides for participants taking weekly and biweekly doses, according to trial data presented at the ENDO annual meeting.
VS-01 safe, well tolerated in patients with decompensated cirrhosis
Versantis announced positive results from a phase 1b clinical trial of VS-01 in patients with decompensated cirrhosis.
Patients with NASH cirrhosis have poorer prognosis than those with HBV
Patients with decompensated cirrhosis due to non-alcoholic steatohepatitis had worse outcomes and more complications than patients with hepatitis B virus, according to study results.
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read
-
Headline News
A potential new paradigm for treating acute migraine: Timolol nasal spray
November 15, 20245 min read -
Headline News
AI-enabled video of skin on face, hands may detect high blood pressure, diabetes
November 15, 20242 min read -
Headline News
‘Troubling’ data show lack of awareness about lung cancer screening
November 15, 20242 min read